Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.81 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.76 |
| ▸ | JAK3 | P52333 | 2/20 | 0.76 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.76 |
| ▸ | KDR | P35968 | 8/20 | 0.76 |
| ▸ | RET | P07949 | 2/20 | 0.74 |
| ▸ | KIF5B | P33176 | 2/20 | 0.74 |
| ▸ | CLK1 | P49759 | 1/20 | 0.72 |
| ▸ | LCK | P06239 | 3/20 | 0.70 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.70 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | GAK | O14976 | 1/20 | 0.68 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.68 |
| ▸ | ABL1 | P00519 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CDK1 | P06493 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | FBP1 | P09467 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5570070 | 0.90 | EGFR (0.85) | EGFRABCG2JAK3ABCB1KDR | |
| SCHEMBL5565204 | 0.88 | KDR (0.79) | EGFRABCG2JAK3KDRRET | |
| SCHEMBL20812874 | 0.86 | EGFR (0.80) | EGFRABCG2JAK3ABCB1KDR | |
| SCHEMBL14095971 | 0.86 | EGFR (0.80) | EGFRABCG2JAK3ABCB1KDR | |
| SCHEMBL29372372 | 0.86 | JAK3 (1.00) | EGFRABCG2JAK3ABCB1KDR | |
| SCHEMBL29711485 | 0.86 | JAK3 (1.00) | EGFRABCG2JAK3ABCB1KDR | |
| SCHEMBL29651 | 0.86 | JAK3 (1.00) | EGFRABCG2JAK3ABCB1KDR | |
| SCHEMBL5864733 | 0.86 | JAK3 (0.79) | EGFRABCG2JAK3ABCB1KDR | |
| SCHEMBL5467825 | 0.85 | EGFR (1.00) | EGFRABCG2JAK3ABCB1KDR | |
| SCHEMBL6664095 | 0.85 | EGFR (0.78) | EGFRABCG2JAK3ABCB1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6358962-B2 | ANTIALLERGENS; ANTITUMOR AGENTS; ANTICANCER AGENTS | PARKER HUGHES INSTITUTE | 2002-03-19 | — | — | US | claimed |
| US-7038049-B2 | Haloanilino quinazolines and therapeutic use thereof | PARKER HUGHES INSTITUTE (US) | 2006-05-02 | — | — | US | disclosed |
| US-20050075353-A1 | Quinazolines and therapeutic use thereof | PARKER HUGHES INSTITUTE (US) | 2005-04-07 | — | — | US | disclosed |
| US-6638939-B2 | Anticancer agents | PARKER HUGHES INSTITUTE | 2003-10-28 | — | — | US | disclosed |
| US-6552027-B2 | 4-((3-hydroxyphenyl)amino),6,7-dimethoxy-quinazoline for example; conjugates with epidermal growth factor | PARKER HUGHES INSTITUTE | 2003-04-22 | — | — | US | disclosed |
| US-20020137757-A1 | Quinazolines and therapeutic use thereof | PARKER HUGHES INSTITUTE (US) | 2002-09-26 | — | — | US | disclosed |
| US-20020111360-A1 | Quinazoline formulations and therapeutic use thereof | PARKER HUGHES INSTITUTE | 2002-08-15 | — | — | US | disclosed |
| US-6358962-B2 | ANTIALLERGENS; ANTITUMOR AGENTS; ANTICANCER AGENTS | PARKER HUGHES INSTITUTE | 2002-03-19 | — | — | US | disclosed |
| US-6316454-B1 | 6,7-Dimethoxy-4-anilinoquinazolines | PARKER HUGHES INSTITUTE | 2001-11-13 | — | — | US | disclosed |
| US-20010016588-A1 | Quinazolines and therapeutic use thereof | HUGHES INSTITUTE (US) | 2001-08-23 | — | — | US | disclosed |
| US-6258820-B1 | ANTITUMOR AGENTS | PARKER HUGHES INSTITUTE | 2001-07-10 | — | — | US | disclosed |
| EP-1082311-A1 | QUINAZOLINES FOR TREATING BRAIN TUMOR | Parker Hughes Institute (US) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999061428-A1 | QUINAZOLINES FOR TREATING BRAIN TUMOR | PARKER HUGHES INSTITUTE (US) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075353-A1 | Quinazolines and therapeutic use thereof | HRH2, HRH4, HNMT | EGFR 1931/4885ABCG2 351/4885JAK3 321/4885 |
| US-20020111360-A1 | Quinazoline formulations and therapeutic use thereof | CMA1, MAST3, MAST1 | EGFR 3336/4885ABCG2 19/4885JAK3 339/4885 |
| US-20020137757-A1 | Quinazolines and therapeutic use thereof | HRH2, HRH4, HNMT | EGFR 1931/4885ABCG2 351/4885JAK3 321/4885 |
| US-20010016588-A1 | Quinazolines and therapeutic use thereof | HRH2, HRH4, HNMT | EGFR 1931/4885ABCG2 351/4885JAK3 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.